EW

Edwards Lifesciences
D

EW

Arincen78/100B
107.460
USD
1.63
(1.54%)
Market Open
Last updated: · Delayed 15 min
Fair valueNot reliable
Q4 FY2026 · Earnings report
EPS estimate 0.66Revenue estimate 1.71B
OverviewFinancialsForecastEarningsCompany

Edwards Lifesciences revenue 1999–2026

Edwards Lifesciences's revenue in Q3 FY2026, the three months to 30 September 2026, was 1.72B USD, up 10.5% on the same quarter a year before. Edwards Lifesciences's revenue over the last twelve months was 6.67B USD, up 13.4% on the twelve months before. In fiscal year 2025 it was 6.07B USD, up 11.5% on the year before.

Last updated 10 Nov 2026 · Next report 9 Feb 2027

Revenue

Growth

Fiscal yearPeriod endingRevenueGrowthGross profitNet income
TTM30 Sept 20266.67B+13.44%5.22B1.02B
FY202531 Dec 20256.07B+11.55%4.74B1.07B
FY202431 Dec 20245.44B+8.57%4.32B4.17B
FY202331 Dec 20235.01B-6.92%3.97B1.40B
FY202231 Dec 20225.38B+2.86%4.22B1.52B
FY202131 Dec 20215.23B+19.29%4.01B1.50B
FY202031 Dec 20204.39B+0.88%3.29B823.40M
FY201931 Dec 20194.35B+16.79%3.19B1.05B
FY201831 Dec 20183.72B+8.37%2.80B722.20M
FY201731 Dec 20173.44B+15.91%2.55B622.10M
FY201631 Dec 20162.96B+18.85%2.16B569.50M
FY201531 Dec 20152.49B+7.35%1.81B494.90M
FY201431 Dec 20142.32B+13.56%1.69B811.10M
FY201331 Dec 20132.05B+7.68%1.50B391.70M
FY201231 Dec 20121.90B+13.17%1.39B293.20M
FY201131 Dec 20111.68B+16.01%1.22B236.70M
FY201031 Dec 20101.45B+9.51%1.04B218.00M
FY200931 Dec 20091.32B+6.76%917.30M229.10M
FY200831 Dec 20081.24B+13.44%828.80M128.90M
FY200731 Dec 20071.09B+5.22%709.80M113.00M
FY200631 Dec 20061.04B+3.92%653.70M130.50M
FY200531 Dec 2005997.90M+7.13%623.30M79.30M
FY200431 Dec 2004931.50M+8.25%561.30M1.70M
FY200331 Dec 2003860.50M+22.23%501.10M79.00M
FY200231 Dec 2002704.00M+1.73%404.90M55.70M
FY200131 Dec 2001692.00M-13.93%368.00M-12.00M
FY200031 Dec 2000804.00M-11.16%381.00M-272.00M
FY199931 Dec 1999905.00M—439.00M82.00M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Edwards Lifesciences revenue growth by segment

Q3 FY2026 against Q3 FY2025

Transcatheter Heart Valves1.24B
+8.0%
Transcatheter Mitral And Tricuspid Therapies209.50M
+44.3%

Edwards Lifesciences revenue by segment over time

Transcatheter Heart Valves Surgical Heart Valve Therapy Transcatheter Mitral And Tricuspid Therapies Critical Care
Fiscal yearTranscatheter Heart ValvesSurgical Heart Valve TherapyTranscatheter Mitral And Tricuspid TherapiesCritical Care
FY20254.49B +9.3%1.03B +4.9%550.60M +56.4%—
FY20244.11B +5.8%981.30M -1.8%352.10M +78.2%—
FY20233.88B +10.3%999.30M +11.9%197.60M +70.2%928.10M +8.5%
FY20223.52B +2.8%893.10M +0.4%116.10M +35.0%855.00M +2.4%
FY20213.42B +19.8%889.10M +16.7%86.00M +105.7%834.90M +15.1%
FY20202.86B +4.4%761.80M -9.5%41.80M +48.2%725.40M -2.0%
FY20192.74B +19.7%841.70M +10.5%28.20M 740.20M +9.7%
FY20182.29B +12.8%761.60M -5.6%— 674.50M +12.2%
FY20172.03B +24.5%807.10M +4.2%— 601.00M +7.3%
FY20161.63B +38.0%774.90M -1.3%— 560.30M +6.0%

See also:Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Edwards Lifesciences's revenue

Source: Financial Modeling Prep